Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207757 | 1.00 | HAVCR2 (0.41) | HAVCR2CNR2TSHRGRIN2BPRKAG1 | |
| SCHEMBL26167975 | 0.86 | MAPT (0.47) | POLBMAPT | |
| SCHEMBL30207719 | 0.86 | MAPT (0.47) | POLBMAPT | |
| SCHEMBL25244008 | 0.85 | FABP3 (0.36) | GRIN2BPTPN11FABP3FABP4 | |
| SCHEMBL30207675 | 0.82 | PTPN11 (0.38) | PTPN11 | |
| SCHEMBL26167978 | 0.82 | PTPN11 (0.38) | PTPN11 | |
| SCHEMBL30824241 | 0.81 | HAVCR2 (0.43) | HAVCR2CNR2TSHRPRKAG1PRKAA1 | |
| SCHEMBL20600167 | 0.81 | HAVCR2 (0.43) | HAVCR2CNR2TSHRPRKAG1PRKAA1 | |
| SCHEMBL26167946 | 0.78 | DHODH (0.33) | GRIN2BPRKAG1PRKAA1PRKAB1DHODH | |
| SCHEMBL30207756 | 0.78 | HSP90AA1 (0.37) | AURKBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-4132911-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | Bayer Animal Health GmbH (DE) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667221-A | Substituted fused oxazines as insect repellent compounds | 拜耳动物保健有限责任公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | H1-5, H1-10, H1-0 | HAVCR2 3082/4885CNR2 2438/4885TSHR 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.